Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 14/20 | 0.45 |
| ▸ | GGPS1 | O95749 | 8/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29574656 | 0.81 | FDPS (0.50) | FDPSGGPS1EP300TP53CYP3A4 | |
| SCHEMBL13197140 | 0.76 | FDPS (0.53) | FDPSGGPS1EP300TP53CYP3A4 | |
| SCHEMBL13201767 | 0.76 | FDPS (0.53) | FDPSGGPS1EP300TP53CYP3A4 | |
| SCHEMBL15732245 | 0.68 | EP300 (0.46) | FDPSGGPS1EP300TP53CYP3A4 | |
| SCHEMBL12557647 | 0.67 | FDPS (0.63) | FDPSGGPS1TP53CYP3A4KDM4E | |
| SCHEMBL19792842 | 0.67 | FDPS (0.63) | FDPSGGPS1TP53CYP3A4KDM4E | |
| SCHEMBL22862035 | 0.65 | FDPS (0.39) | FDPSGGPS1EP300CES2CES1 | |
| SCHEMBL9359973 | 0.62 | CYP3A4 (0.50) | FDPSGGPS1EP300TP53CYP3A4 | |
| SCHEMBL18290369 | 0.62 | EP300 (0.56) | FDPSGGPS1EP300CES2CES1 | |
| SCHEMBL8855131 | 0.57 | KARS1 (0.51) | EP300TP53CYP3A4MEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299275-B2 | Process for producing carnosol from carnosic acid using hydrogen peroxide or peracids | DSM IP ASSETS B.V. (NL) | 2012-10-30 | — | — | US | disclosed |
| US-20110144357-A1 | PROCESS FOR PRODUCING CARNOSOL FROM CARNOSIC ACID USING HYDROGEN PEROXIDE OR PERACIDS | DSM IP ASSETS B.V. (NL) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144357-A1 | PROCESS FOR PRODUCING CARNOSOL FROM CARNOSIC ACID USING HYDROGEN PEROXIDE OR PERACIDS | FECH, CROCC, CAT | FDPS 77/4885GGPS1 672/4885EP300 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.